#EHA2025
#EHA2025
Honoured to have been involved in this study and happy to see it finally published in @bloodjournal.bsky.social. Big Kudos to #DarjaKarpova and #HectorHuerbaEncabo for driving the project 🥇🥇🥇. Read full article here: ashpublications.org/blood/articl...
Congrats 🥂
🙏🙏Thanks🙏🙏@oncodaily.bsky.social and @elisabettabonzano.bsky.social for highlighting our recent paper on #HER3/NRG1 and #FGFR1 signaling in #CTC from #brestcancer patients published in @naturecancer.bsky.social @dkfz.bsky.social
Here the link 👇👇👇👇
rdcu.be/d61IZ
Interested in understanding how #CTCs colonize distant organs and resist to therapy? Go check the latest paper from #RobertoWürth from #AndreasTrumpp lab on @naturecancer.bsky.social...
🚨SpoilerAlert: we can hijack those mechanisms to establish long term in vitro #CTC derived #organoids
Let's start the 2025 with a blast 🎇. Out today on @naturecancer.bsky.social Würth et al., on HER3/NRG1 and FGFR1 compensatory mechanism in CTCs and how to hijack that for long term in vitro culture.
#CTC #breastcancer #liquidbiopsies #NGS #personalizedmedicine @dkfz.bsky.social #HISTEM
rdcu.be/d5pGe
Are you interested in understanding non-genetic therapy resistance mechanisms in cancer? Do you have previous bioinformatic experience with single-cell epigenomic data analysis? Then consider applying to this postdoctoral position in our division:
jobs.dkfz.de/en/jobs/1673...
Join us at FMI as a Junior Group Leader! A unique opportunity to set up your lab in a vibrant international research institute with world-class research groups and facilities, generous core funding, a collegial and inclusive culture - and great colleagues 🤓!
Hello, can you also add me?
Extremely proud to see my PhD project exploring intra-tumor heterogeneity in complex karyotype AML finally out in @NatureGenet! 🎉 👩🏻🔬
They say that 10,000 hours make you an expert, so I guess after more than five years of work I’m half-way there 😅 ⬇️1/5
www.nature.com/articles/s41...
Congrats Maija 😎🥳